All In Biotech

Drug Trial Radar · NCT07946367

Dual-targeting of B & T Cell Pathways Evaluation Trial

Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Aug 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Diabetes Free, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

Conditions

  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)
  • Idiopathic Inflammatory Myopathies (IIM)

Interventions

  • DFI205 bispecific antibodyDrug

    A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the initial safety and tolerability of DFI205 in adults with SARDsTime frame: Up to 1 year post-dosing
  2. To monitor immune reconstitution after completion of dosing with DFI205Time frame: Up to 1 year post-dosing
  3. To monitor immune response to DFI205Time frame: Up to 1 year post-dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitaetsklinikum Erlangen AöR

    Erlangen, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.